A 16‐month‐long experience of COVID‐19 in allogeneic haematopoietic stem cell transplantation recipients: An SFGM‐TC multicentre cohort study

• Published in: British journal of haematology Vol. 201; no. 6; pp. 1066 - 1071
• Main Authors: Xhaard, Aliénor, Xhaard, Constance, Rubio, Marie‐Therese, Berceanu, Ana, Botella‐Garcia, Carmen, Coman, Tereza, Tavernier, Emmanuelle, Labussière‐Wallet, Hélène, Chevallier, Patrice, Legrand, Faezeh, Thiebaut, Anne, Menard, Anne‐Lise, Paillard, Catherine, Chantepie, Sylvain, Robin, Marie, Nguyen, Stephanie
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.06.2023
• Subjects: allogeneic hematopoietic stem cell transplantation; Allografts; Cohort analysis; COVID-19; COVID-19 - etiology; Hematology; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic stem cells; Humans; Immunosuppressive Agents - adverse effects; infection; Mortality; Respiratory tract diseases; Retrospective Studies; Risk Factors; SARS‐CoV‐2; Stem cell transplantation; COVID-19; SARS-CoV-2; infection; allogeneic hematopoietic stem cell transplantation
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.18754

Summary This 16‐month‐long multicentre retrospective study of 225 allogeneic haematopoietic stem cell transplantation (alloHSCT) recipients with COVID‐19 examines risk factors for severity and mortality, describing the successive waves of infections (from March to June 2020 and from August 2020 to June 2021). We confirm the negative role of low respiratory tract disease and immunosuppressive treatment. We highlight significantly lower percentages of severe forms and COVID‐19‐related mortality during the second wave. Monthly comparative evolution of cases in alloHSCT recipients and in the French population shows a higher number of cases in alloHSCT recipients during the first wave and a decrease from February 2021.